Drug
APP13007 clinical trials
How studies write it
Studies that test it under each name
Name
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Pain
- 1
Who runs them
Industry 3 · Other 0
Formosa Pharmaceuticals, Inc. (3)
Studies
Open first, then newest update. How each study uses APP13007 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-studyCompletedPhase 3Formosa Pharmaceuticals, Inc.NCT04810962Written as APP13007, 0.05%
- Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract SurgeryCompletedPhase 3Formosa Pharmaceuticals, Inc.NCT04739709Written as APP13007, 0.05%
- A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract SurgeryCompletedPhase 2Formosa Pharmaceuticals, Inc.NCT04089735Written as APP13007, 0.05%